Vicente Anido, Jr. nominated for election to Nicox's Board of Directors

Vicente Anido, Jr. nominated for election to Nicox's Board of Directors 
SOPHIA ANTIPOLIS CEDEX, FRANCE -- (Marketwired) -- 04/26/13 --  Nicox
S.A. (NYSE Euronext Paris: COX) today announced that the Company's
Board of Directors has nominated Vicente Anido, Jr., PhD., to be
elected to the Board.
 Dr. Anido is a highly respected and
experienced leader in the ophthalmology
sector. He most recently
served as President and Chief Executive Officer of
Pharmaceuticals prior to its acquisition by Bausch + Lomb. The
election of Dr.
Anido to Nicox's Board will be voted on at the
Company's 2013 Ordinary Shareholder Meeting, which will be convened
for June 6, 2013. 
"The Board is pleased to propose Vince Anido as a Board member of
Nicox. Vince
has a wealth of experience in the management of
pharmaceutical companies, particularly in the ophthalmic area. We
believe he would be a significant addition to the existing strength
and combined experience of the Nicox Board as we work towards
building an international ophthalmology business," said
Garufi, Chief Executive Officer of Nicox. 
About Vicente Anido, Jr. 
From 2001 to 2012, Dr. Anido was President, Chief Executive Officer
and a Director of ISTA Pharmaceuticals, a US-based ophthalmic
pharmaceutical company.
Prior to this, he was general partner of
Windamere Venture Partners, served as
President and CEO of CombiChem,
Inc., a biotechnology company, and was President
of the Americas
Region of Allergan, a specialty pharmaceutical company focusing
ophthalmology, dermatology and neuromuscular indications. Dr. Anido
currently serves on the Board of Directors of QLT Inc. and
Inc., two NASDAQ-listed pharmaceutical companies, and was
recently named Chairman of the Board of Directors of Aerie
Pharmaceuticals, a US private ophthalmic company. 
Dr. Anido received a B.S. in Pharmacy, an M.S. in Pharmacy
Administration from
West Virginia University and a Ph.D. in Pharmacy
Administration from the University of Missouri. 
Information on the 2013 Ordinary Shareholder Meeting is available on
the Nicox internet website: 
About Nicox 
Nicox  (Bloomberg:  COX:FP,  Reuters:  NCOX.PA)  is  creating  a  new
 mid- sized
international  player  in  the  ophthalmic  market  by 
building  a diversified
portfolio  of  innovative  therapies  and 
diagnostic  tools. With a heritage of scientific,  business
development  and commercial  expertise, the  Nicox team is focused on
developing and marketing novel pharmaceuticals and diagnostic
that can help people to enhance their sight. In the United
States, Nicox markets
AdenoPlus(TM), a test for the differential
diagnosis of acute conjunctivitis in- licensed from RPS(R). 
The  Company's pipeline  includes latanoprostene  bunod, a  novel
drug- candidate
based  on Nicox's proprietary nitric oxide
(NO)-donating R&D platform, developed
in  collaboration with Bausch +
Lomb for the potential treatment of glaucoma and ocular hypertension.
Further NO-donating compounds are under development in
non-ophthalmic  indications, notably through partners, including
Merck (known as MSD outside the United States and Canada) and Ferrer. 
Nicox  S.A.  is  headquartered  in  France  and  is  listed  on 
Euronext Paris
(Compartment B: Small Caps). For more information
please visit 
This press release contains certain forward-looking statements.
Although the
Company believes its expectations are based on reasonable
assumptions, these
forward-looking statements are subject to numerous
risks and uncertainties, which could cause actual results to differ
materially from those anticipated in the forward-looking statements. 
Risks factors which are likely to have a material effect on Nicox's
business are presented in the 4th chapter of the << Document de
reference, rapport financier annuel et rapport de gestion 2012 >>
filed with the French Autorite des Marches Financiers (AMF) on March
22, 2013 and available on Nicox's website ( and on the
AMF's website (
Vicente Anido, Jr. nominated for
election to Nicox's Board of Director: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: NICOX via Thomson Reuters ONE 
Nicox Contacts 
Gavin Spencer
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 
Media Relations
FTI Consulting 
Jonathan Birt
D +44 (0)20 7269 7205
M +44 (0) 7515 597 858 
Stephanie Cuthbert
D +44 (0)20 3077 0458
M +44 (0) 7843 080947 
Nicox S.A.
Drakkar 2
Bat D
2405 route des Dolines
CS 10313
Sophia Antipolis
06560 Valbonne, France
T: +33 (0)4 97 24 53 00
F: +33 (0)4 97 24 53 99
Press spacebar to pause and continue. Press esc to stop.